By using the inflammatory biomarkers; the study describing that the inflammatory markers and changing in gene expression that have been linking to depression and suicide. This determining that the stabilization of ovarian hormones estradiol; and progesterone may help lower symptoms associating with suicidality among females with longstanding thoughts of suicide.
While estradiol and progesterone rise and fall over the course of the menstrual cycle, the hormones plummet to their lowest levels just before and during menses. Suicide attempts occur most frequently either right before, during or right after menstrual bleeding in women. The study comparing compare symptoms of suicidality among the participants across two experimental conditions.
Biomarkers predicting suicide risk
As one menstrual cycle where placebos are given during the perimenstrual period and one cycle where estradiol and progesterone are stabilized during the perimenstrual period. Participants will record levels of depression, hopelessness, and suicidality daily on their smartphones. Inflammatory markers include C reactive protein (CRP), erythrocyte sedimentation rate, plasma viscosity, fibrinogen, ferritin; and several other acute phase proteins, though only the first three are commonly referred to as inflammatory markers.
Blood will be drawn each week during experimental conditions to evaluate levels of estradiol and progesterone as well as inflammatory markers and changes in gene expression that have been linked to depression and suicide. The metadata, but not the content of the text; is analyzing using an artificial intelligence-basing machine learning approach to identify digital biomarkers of manic and depressive episodes in people with bipolar disorder.
Levels of hormone metabolites
Participants also will provide blood samples to determine levels of hormone metabolites such as allopregnanolone, and the expression of genes related to the brain’s ability to create allopregnanolone. Allopregnanolone binds to receptors for the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. These receptors also are the targets of anti-anxiety drugs such as benzodiazepines. The first-ever drug to treat postpartum depression, approved this year, is a synthetic version of allopregnanolone.
These receptors also are the targets of anti-anxiety drugs such as benzodiazepines. The first-ever drug to treat postpartum depression, approved this year, is a synthetic version of allopregnanolone. The study can identify biomarkers through our blood testing and through analyzing data from BiAffect; we may be able to more accurately predict who is at the highest risk and at what times; and take action to help that particular person; such as ensuring they get extra support or treatment during certain times in their cycle.